Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Safety and efficacy of intraurethral alprostadil in patients with erectile dysfu...
Journal Information
Vol. 39. Issue 10.
Pages 635-640 (December 2015)
Share
Share
Download PDF
More article options
ePub
Visits
37
Vol. 39. Issue 10.
Pages 635-640 (December 2015)
Original article
DOI: 10.1016/j.acuroe.2015.10.001
Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors
Eficacia y seguridad del alprostadil intrauretral en pacientes con disfunción eréctil refractarios al tratamiento mediante inhibidores de la 5-fosfodiesterasa
Visits
...
P. Garrido-Abad
Corresponding author
pgabad@hotmail.com

Corresponding author.
, B. Sinués-Ojas, L. Martínez-Blázquez, P. Conde-Caturla, M. Fernández-Arjona
Servicio de Urología, Hospital del Henares, Coslada, Madrid, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Table 1. Etiology of erectile dysfunction in responders and nonresponders (depending on the SAE).
Table 2. Adverse effects after the application of MUSE®.
Show moreShow less
Abstract
Introduction

Phosphodiesterase-5 inhibitors (PDE5i) are the first choice for treating erectile dysfunction (ED) but are not always effective. The aim of this study was to present our experience in treating patients with ED, refractory to treatment with PDE5i, using intraurethral alprostadil (MUSE).

Material and methods

We conducted a review of 82 patients with ED and no response to PDE5i, from March 2013 to October 2014. Forty-seven patients (57%) had hypertension (AHT), 24 (29%) had diabetes (DM) and 20 (24%) had AHT and DM. Additionally, 19 (23%) had undergone radical prostatic (RP) surgery. The patients were evaluated after the treatment was applied and at 4 weeks using the following validated questionnaires: International Index of Erectile Function (IIEF-5/SHIM), Global Assessment Questionnaire (GAQ), Sexual Encounter Profile (SEP) and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS).

Results

The mean patient age was 60.5 years (40–80), and the mean follow-up was 11.3 months (1–20). Sixty-eight percent of the treated patients responded to MUSE® (74% in the AHT group, 65% in the AHT+DM group, 62.5% in the DM group and 58% in the RP group). The mean IIEF-5 score was 11.7±4.7, which increased to 18.6±4.9 after MUSE was administered (P=.027). The mean EDITS score at 4 weeks was 61.6 (6–81.9). The most common adverse effect was urethral burning, which occurred in 24 patients (29%). There were no cases of urinary tract infection, syncope or priapism.

Conclusions

Intraurethral alprostadil is an effective treatment and has a broad safety profile for treating patients with erectile dysfunction refractory to oral treatment with PDE5i.

Keywords:
Erectile dysfunction
Alprostadil
Intraurethral
Resumen
Introducción

Los inhibidores de la 5-fosfodiesterasa (IPDE5) son de primera elección para el tratamiento de la disfunción eréctil (DE), pero no siempre son efectivos. El objetivo es presentar nuestra experiencia en el tratamiento de pacientes con DE, refractaria al tratamiento con IPDE5, mediante alprostadil intrauretral.

Material y métodos

Revisión de 82 pacientes con DE, sin respuesta a IPDE5, desde marzo de 2013 hasta octubre de 2014. De ellos, 47 (57%) presentaban hipertensión (HTA), 24 (29%) diabetes (DM), y 20 (24%) HTA y DM. Además, 19 (23%) habían sido tratados mediante cirugía radical prostática (PR). Fueron evaluados en la consulta tras la aplicación del tratamiento y a las 4 semanas mediante los cuestionarios validados: International Index of Erectile Function (IIEF-5/SHIM), Global Assessment Questionnaire (GAQ), Sexual Encounter Profile (SEP) y Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS).

Resultados

La edad media fue de 60,5 años (40-80), con seguimiento medio de 11,3 meses (1-20). El 68% de los pacientes tratados respondieron a MUSE® (74% en el grupo de HTA, 65% en el de HTA+DM, 62,5% en el de DM y 58% en el de PR). La media del IIEF-5 era de 11,7±4,7, y ascendió hasta 18,6±4,9 tras MUSE® (p=0,027). La media de la puntuación del EDITS a las 4 semanas fue de 61,6 (6-81,9). El efecto adverso más frecuente fue el escozor uretral, que ocurrió en 24 pacientes (29%). No se observó ningún caso de infección del tracto urinario, síncope ni priapismo.

Conclusiones

El alprostadil intrauretral es un tratamiento efectivo y con un amplio perfil de seguridad para tratar a aquellos pacientes con disfunción eréctil refractaria al tratamiento oral con IPDE5.

Palabras clave:
Disfunción eréctil
Alprostadil
Intrauretral

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 22,50 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.